|
 Chief Financial Officer Kalina Scott is leaving as Polyphor
redirects its attention to the late-stage immuno-oncology asset
balixafortide that it hopes proves effective against a type of
metastatic breast cancer. Scott, who joined in 2017, will be
replaced by Hernan Levett, now CFO at Auris Medical.
Polyphor's prospects and its share price plunged this year when it
halted a trial of its intravenous murepavadin antibiotic against
pneumonia due to a risk it could damage kidneys. While it is still
developing inhaled murepavadin for cystic fibrosis, the scotched
trial was a major blow.
"The company expects inhaled murepavadin should not lead to kidney
toxicity, given its much lower dose and local administration,"
Polyphor said in a statement with its first-half earnings report.
In other management changes, Frank Weber is leaving the board to
become chief medical and development officer, Gokhan Batur is
joining as chief commercial officer and oncologist Frank Ringeisen
is joining as the new cancer head.
[to top of second column] |
Polyphor's first-half loss widened to 27.9 million Swiss francs
($28.6 million), from about 21 million francs in the same period a
year earlier. Cash levels fell to 97.2 million francs on June 30,
down from 133.8 million francs six months earlier.
The shares cost less than less than 7 francs, about a fifth of
levels reached after their 2018 initial public offering. Its market
capitalization, once 400 million francs, is now less than 80 million
francs.
(Reporting by John Miller; Editing by Edmund Blair)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
